T he efficacy and safety of pharmacological and behavioral smoking cessation interventions have been examined in multiple randomized controlled trials (RCTs), with subsequent meta-analyses showing that such interventions are efficacious at increasing quit rates.
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Methods
Our systematic review and network meta-analysis was performed after a prespecified protocol and is reported using the guidelines described in PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension for reporting of systematic reviews incorporating network meta-analyses. 8 
Data Sources
We systematically searched Ovid EMBASE, Ovid PsycINFO, Ovid MEDLINE, PubMed, and the Cochrane Tobacco Addiction Group Specialized Register from inception to June 2015 to identify RCTs of pharmacological and behavioral smoking cessation interventions in CVD patients. The search strategy was designed and conducted by an experienced health librarian (G.C.G.). No language restriction was used in the search. A combination of text words, Medical Subject Headings (MeSH), EMTREE terms, and the Thesaurus of Psychological Index Terms was used for smoking cessation, interventions, and CVD (Tables I through V in the Data Supplement) . Additionally, we scanned the references of previous reviews on smoking cessation in CVD and hospitalized populations [9] [10] [11] [12] [13] [14] to retrieve studies that were not identified by our primary search.
Study Selection
The titles and abstracts of identified publications were screened by 2 independent reviewers, with those deemed relevant by at least one reviewer carried forward for full-text review, where disagreements were resolved by consensus. Included studies were RCTs that investigated the efficacy or safety of a smoking cessation intervention (pharmacological or behavioral) compared with an appropriate reference group (placebo for pharmacological interventions and usual care for behavioral interventions). Pharmacotherapies of interest were varenicline, bupropion, or nicotine replacement therapy (NRT), including patch, gum, inhaler, or spray, and behavioral therapies, including inhospital counseling (inpatient counseling only), telephone counseling (≥2 telephone support sessions for outpatients), or individual counseling (≥1 outpatient counseling sessions). Inclusion was restricted to RCTs conducted in smokers with CVD or to RCTs where smoking cessation outcomes for this population were reported. CVD included the following conditions: angina pectoris, coronary artery disease, coronary artery bypass grafting, myocardial infarction, heart failure, peripheral artery disease, transient ischemic attack, and stroke. Included studies had to report smoking cessation either as continuous or point prevalence abstinence by treatment group at 6 or 12 months (allowing for a 6-week grace period). Biochemical validation of abstinence was not an inclusion criterion; however, subgroup analyses involving this study characteristic were performed.
Smoking reduction and maintenance studies were excluded, as were those that examined general lifestyle interventions not specifically aimed at smoking cessation (eg, multifactorial CVD prevention programs). Studies that randomized participants who were described as not motivated to quit or did not have a precise quit date were also excluded. Trials that included patients who were not motivated to quit were excluded because treatment effects for behavioral and pharmacological therapies are likely different in such patients and their inclusion would violate the consistency assumption if such patients were distributed differentially across treatment groups. 15 Importantly, only trials that explicitly stated that their population included patients who were not motivated to quit were excluded; with patients having given informed consent to participate in a smoking cessation trial, it was assumed that patients were motivated unless stated otherwise (Table VI in the Data Supplement). Observational studies, case reports, case series, letters to editors, editorials, reviews, conference abstracts, commentaries, and guidelines were excluded. Finally, studies published in a language other than English or French were excluded.
Data Extraction
Data extraction was performed independently by 2 reviewers with any disagreements resolved by consensus or by a third reviewer. Study characteristics were extracted, including study population (inpatient versus outpatient, acute versus stable) and intervention details. For pharmacotherapy RCTs, type and dosage were extracted. For behavioral therapy RCTs, intensity level, counseling type, duration and number of sessions, usual care definition, and adjunct pharmacotherapy use were extracted. Outcomes were point prevalence of abstinence and continuous abstinence from smoking at 6 and 12 months. Patient demographics, smoking habits, and use of biochemical validation were also extracted. Safety outcomes extracted included the number of patients with adverse events, serious adverse events, and cardiovascular events. Multigroup trials were treated as separate trials using the same reference group.
Classification of Outcomes
Outcomes were classified following the criteria from a previous systematic review on pharmacotherapies for smoking cessation.
1 Point prevalence of abstinence was defined as no smoking in the 7 days before the follow-up. Continuous abstinence was defined as a complete cessation from the quit date to the latest follow-up. Because of the heterogeneity of reported outcomes between studies, we analyzed smoking abstinence according to the most rigorous criterion provided by each trial: (1) continuous abstinence at 12 months; (2) continuous abstinence at 6 months; (3) point prevalence of abstinence at 12 months; and (4) point prevalence of abstinence at 6 months, with priority given to any biochemically validated outcome. All analyses were intention-to-treat, with all patients who were alive but lost to follow-up considered to have returned to smoking, a common assumption in smoking cessation trials. 16 
Quality Assessment
Quality assessment was performed by 2 independent reviewers using the Cochrane Collaboration's tool for assessing risk of bias, 17 with disagreements resolved by consensus or by a third reviewer. This tool assesses 6 potential sources of bias: sequence generation; allocation concealment; blinding of participants, outcome assessors, and personnel; incomplete outcome data; selective outcome reporting; and other potential sources of bias. A score of high, low, or unclear was
WHAT IS KNOWN
• Several randomized controlled trials and subsequent meta-analyses have demonstrated that pharmacological and behavioral smoking cessation therapies are efficacious at increasing smoking abstinence in the general population.
• However, participants in these trials were generally healthy, and the generalizability of these data to patients with cardiovascular disease is unclear.
WHAT THE STUDY ADDS
• Our network meta-analysis of 24 trials of pharmacotherapies and behavioral therapies suggests that, among patients who are motivated to quit smoking, varenicline and bupropion are efficacious for smoking cessation in patients with cardiovascular disease, whereas available data about nicotine replacement therapies are inconclusive.
• Individual and telephone counseling also seem to be efficacious in this patient population.
• Available evidence suggests that varenicline is the most efficacious smoking cessation therapy in patients with cardiovascular disease who are motivated to quit smoking, although more safety data are needed.
assigned for each domain. All RCTs that met our inclusion criteria were included, regardless of their quality.
Statistical Analysis
Relative risks (RRs) and 95% confidence intervals (CIs) were generated using DerSimonian and Laird random-effects models with inverse variance weighting. In our primary analysis, count data were pooled, and heterogeneity was estimated by the I 2 statistic. Stratified analyses were performed based on the nature of CVD (stable versus acute) and the presence of biochemical validation. Network meta-analysis was used to compare the efficacy of interventions that may or may not have been directly compared with each other using the graph-theoretical approach by Rücker. 18 This approach originated from the graph-theoretical methods that were developed for the electrical network theory. In the case of a pairwise meta-analysis with direct comparisons, this approach simplifies to the fixed-effect model estimate. The network geometry was explored graphically. The transitivity, homogeneity, and consistency assumptions were assessed via subgroup analyses (by type of therapy, CVD subtype, and the exclusion of behavioral trials in which the availability of pharmacotherapy was differential between treatment groups) and the I 2 statistic. Consistency was assessed by running inconsistency models and assessing the residuals in inconsistency plots. Treatment rankings and P scores were calculated, and rankogram curves were constructed. All statistical analyses other than inconsistency models were performed using R version 3.2.1; direct comparisons were analysed using the meta package, and network meta-analyses were performed with the netmeta package. 19 Inconsistency models were created using NetMetaXL and WinBUGS. 20 
Results
Search Results
Our initial electronic search identified 2967 potentially relevant publications ( Figure 1 ). After the removal of 814 duplicates, the titles and abstracts of 2153 relevant publications were screened for eligibility, and 198 were selected for full-text review, 22 of which met our inclusion criteria. A list of the full texts that did not meet our inclusion criteria is presented in the Data Supplement. The handsearch of reference lists of previous reviews identified 2 additional RCTs 21,22 that had not been retrieved by our electronic search. Thus, a total of 24 RCTs 3-5,7,21-40 were included in our systematic review and meta-analysis. One RCT had 2 behavioral intervention arms; these 2 arms were treated as 2 separate trials and compared with the same usual care group.
Study and Patient Characteristics
In total, 6761 patients were randomized in the 24 included studies: 2095 in the 7 pharmacotherapy trials and 4666 in the 17 behavioral therapy trials (Tables 1 and 2) , with sample sizes ranging from 40 to 643. The 7 pharmacotherapy trials examined 12-month continuous abstinence, with 6 biochemically validating abstinence. All 7 studies had a cointervention in the form of personalized counseling, with the number of sessions ranging from 3 to 25.
Of the 17 behavioral interventions trials, 5 examined 12-month continuous abstinence, with 15 biochemically validating abstinence. Seven trials did not provide any form of adjunct pharmacotherapy, 5 provided it for both the control and the intervention group, and 3 trials provided it only for the intervention group. The type of behavioral intervention was most often motivational support (10 trials), with only 3 trials offering cognitive behavioral therapy. On average, in-hospital counseling trials offered 44 minutes of intervention, telephone counseling trials 99 minutes, and individual counseling trials 233 minutes. 
Quality Assessment
Overall, the pharmacotherapy trials had a low risk of bias (Table VII in the Data Supplement). Three studies had insufficient information about sequence generation and allocation concealment, and those were rated as having an unclear risk of bias. The studies had a low risk of bias for all other criteria, except one trial that had a high risk of bias for selectively reporting certain outcomes.
Among the 17 behavioral therapy RCTs that were included in this meta-analysis, 7 trials had insufficient information about sequence generation and 9 for allocation concealment, resulting in an unclear risk of bias for those domains. All behavioral trials had a high risk of bias for blinding of participants and personnel; this was expected given the nature of behavioral interventions. In addition, there were 2 studies with a high risk of having incomplete outcome data because of losses to follow-up that were not accounted for in the analysis. Four studies had a high risk of selective outcome reporting and 1 gave insufficient information for this domain. Seven studies had a high risk of other biases for issues related to missingness and imbalances in baseline characteristics between treatment groups.
Efficacy of Pharmacotherapies and Behavioral Therapies
In our direct comparisons of pharmacotherapies, the use of bupropion and NRTs for smoking cessation produced inconclusive results, although the possibility of some benefit is likely, particularly for bupropion ( Figure 2 ; Table VIII in the  Data Supplement) . Interestingly, when data were stratified by stable and acute CVD populations, a difference in efficacy was observed ( Figure I in the Data Supplement), with the one study conducted in stable CVD patients 24 finding bupropion to be highly efficacious compared with placebo (RR: 2.46; 95% CI, 1.63-3.71), whereas the pooled result for acute CVD patients suggested little to no benefit (RR: 1.16; 95% CI, 0.90-1.50). The efficacy of varenicline compared with placebo was only assessed in one study, 25 which found varenicline to be highly efficacious compared with placebo in stable CVD patients (RR: 2.64; 95% CI, 1.72-4.06; Figure 2 ).
In our direct comparison of behavioral therapies, we found that in-hospital counseling 7, [26] [27] [28] was not efficacious at increasing smoking abstinence (Figure 3) . However, as the intensity of the behavioral interventions increased, greater increases in smoking abstinence were observed; telephone counseling 26, [29] [30] [31] [32] [33] [34] [35] [36] was 50% more efficacious than usual care (RR: 1.50; 95% CI, 1.15-1.97), and individual counseling 21, [37] [38] [39] [40] was 68% more efficacious than usual care (RR: 1.68; 95% CI, 1.13-2.48; Figure 3 ). Stratified analyses according to stable and acute CVD subtypes were also performed for behavioral therapies (Figures II through IV in the Data Supplement). Telephone counseling was efficacious in both the stable and acute subgroups; however, the effect appeared greater in the patients with acute CVD (RR: 1.96; 95% CI, 1.17-3.29) than in those with stable CVD (RR: 1.24; 95% CI, 1.04-1.48).
Network Meta-Analysis
In indirect comparisons via network meta-analysis, we first compared all pharmacological and behavioral therapies to a single reference group consisting of placebo or usual care (Figure 4) . This analysis suggests that bupropion is an efficacious smoking cessation therapy (RR: 1.42; 95% CI, 1.01-2.00). For all other therapies, results were similar to those obtained in direct comparisons, with varenicline being the most efficacious therapy (RR: 2.64; 95% CI, 1.34-5.21), followed by individual (RR: 1.64; 95% CI, 1.17-2.28) and telephone counseling (RR: 1.47; 95% CI, 1.15-1.88). We then compared each therapy to each other (Table 3) . Because of the wide 95% CIs obtained, data are insufficient to definitively demonstrate that one therapy is superior to another. However, varenicline seems to be more efficacious when compared with the placebo/usual care group (RR: 2.64; 95% CI, 1.34-5.21) than all the other pharmacological and behavioral treatments. As with our direct comparisons, a trend was observed where increasing intensity of behavioral therapy was associated with greater efficacy for smoking cessation. Surface under the cumulative ranking curve values and rankograms suggest that varenicline (P score=0.96) and individual counseling (P score=0.72) ranked as the most efficacious treatments (Table IX and Figure V in the Data Supplement).
The geometry of the treatment network was described using diagrams of all comparisons between treatments in a network (Figures VI and VII in the Data Supplement). The shape of the network is mainly star shaped. In addition, diversity and co-occurrence were assessed. First, when assessing diversity, we observed that the network is moderately complex, with 6 interventions studied for smoking cessation. These interventions seem to have been studied slightly disproportionately. Second, when examining the network for co-occurrence, we observed that not all pairs were studied equally. The behavioral interventions have been studied more often than the pharmacotherapy interventions. This irregularity is normal because pharmacotherapy trials are more difficult to conduct because of the more invasive nature of the therapy. Additionally, inconsistency plots for fixed-and random-effects models (Figures VIII and IX in the Data Supplement) did not show signs of important inconsistency between trials in the network.
Safety of Pharmacotherapies and Behavioral Therapies
Safety data extracted from the pharmacotherapy trials showed a slightly higher number of adverse cardiovascular events in the treatment arm of the studies (Table 4) . However, given the insufficient number of RCTs reporting safety data and the varying definitions of adverse cardiovascular events, it was ACS indicates acute coronary syndrome; BV, biochemically validated; C, control; CA, continuous abstinence; CABG, coronary artery bypass grafting; CBT, cognitive behavioral therapy; CHD, coronary heart disease; CVD, cardiovascular disease; I, intervention; IG, intervention group; NRT, nicotine replacement therapy; PAD, peripheral vascular disease; and PP, point prevalence of abstinence.
not possible to pool these data across trials or draw meaningful quantitative conclusions.
Sensitivity Analysis
We performed separate network analyses for pharmacotherapies and behavioral therapies, and the results were similar to those of our primary network analysis, supporting the assumption of homogeneity of comparison groups (Figures X and XI in the Data Supplement). In addition, we repeated our network meta-analyses excluding behavioral trials in which pharmacotherapies were only available to patients in the active treatment group; the results were consistent with those of our primary analysis (Table X in 
Discussion
We designed this systematic review and network meta-analysis to determine the efficacy and safety of smoking cessation pharmacotherapies and behavioral therapies in patients with CVD who are motivated to quit smoking. Our results for NRTs were inconclusive because of wide CIs. However, available evidence suggests that bupropion is efficacious at increasing abstinence in patients with CVD. To date, only one study has assessed varenicline use in this population, and this study found that varenicline is highly efficacious in patients with stable CVD. We also observed that increasing intensity of the behavioral intervention was positively associated with increasing smoking abstinence, with telephone counseling Our network meta-analysis ranked varenicline and individual counseling as the most efficacious smoking cessation treatments in this population.
Cardiac patients are at a higher risk for cardiovascular events compared with the general population, resulting in a greater motivation to quit smoking after a cardiac event.
11
It is, therefore, not surprising to observe different treatment effects in CVD patients and those from the general population. Trials studying the efficacy of pharmacotherapies in the CVD population remain scarce despite the well-established benefits of smoking cessation in this population, including decreased risks of stroke and myocardial infarction and lower mortality rates from CVD. 41 This may be related to safety concerns surrounding the use of smoking cessation pharmacotherapies during the acute period. 4 For example, there is a relative contraindication to NRT use in the 2 weeks post-myocardial infarction as NRT increases blood pressure and heart rate, particularly in cardiovascular patients. 42 Nonetheless, NRT is the most widely prescribed smoking cessation drug, and it is a central component of the Ottawa Heart Model 43 and the Clinical Practice Guidelines of 2008 for treating tobacco dependence, 44 standards of care in Canada and the United States, respectively. Safety concerns also exist about the use of varenicline in patients with CVD. One RCT showed a higher number of cardiovascular adverse events in the group taking varenicline, but the 95% CI was wide (6.5 versus 6.0%; difference: 0.5%; 95% CI, −3.1 to 4.1%). 25 A meta-analysis found an increased risk of CVD with varenicline in all patients 45 including cardiovascular-related death, nonfatal myocardial infarction, and nonfatal stroke, but subsequent meta-analyses concluded that there was no association with varenicline 46 or any pharmacotherapy. 47 In addition, an observational study conducted by the US Mini-Sentinel system found no evidence of an increased risk. 48 On the basis of the available evidence, the US Food and Drug Administration has concluded that, although an increased risk of major cardiovascular events cannot be ruled out, the health benefits attributable to increased cessation with varenicline suggest that benefits likely outweigh potential harms. 49 Concerns of neuropsychiatric harms of varenicline and bupropion also exist, including changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. 50, 51 With most trials excluding patients with a history of neuropsychiatric disease, neuropsychiatric adverse event data are limited. However, the recently completed the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial found no increase in neuropsychiatric adverse events among patients randomized to varenicline or bupropion relative to those randomized to nicotine patch or placebo. 52 We identified 7 previous systematic reviews on the efficacy of smoking cessation interventions in CVD patients. Overall, the pharmacotherapy reviews found greater abstinence with active treatment. 11, 12, 53 The reviews that assessed the effect of the combination of pharmacotherapy and behavioral therapy had inconsistent results. 13, 14 The 2 systematic reviews that examined only behavioral therapies found higher cessation rates with higher intensity behavioral interventions. 9, 10 These systematic reviews are outdated; with at least 4 new RCTs meeting our inclusion criteria have been published since the searches for these previous reviews were conducted. The present study, thus, provides a more contemporary synthesis of the literature and is, to our knowledge, the first to include both RRs and 95% confidence intervals were estimated using random-effects models. RRs are comparing the treatment in the far left column to that listed at the top of the column. NRT indicates nicotine replacement therapy; and RR, risk ratio.
direct and indirect comparisons of smoking cessation therapy use in this patient population. The results of this study, along with patient and physician preference, and consideration of the issue of polypharmacy in this population, should be considered when determining the most appropriate choice of smoking cessation therapy in CVD patients.
Our study has some potential limitations. First, some heterogeneity existed in the definition of smoking abstinence, and there were an insufficient number of included trials to conduct sensitivity analyses by abstinence definition. Second, in our network meta-analysis comparing all treatments, we made 2 key assumptions. The first was the transitivity assumption, which states that patients in the network had equal chances of getting the treatment. To assess whether this assumption was met, we conducted several subgroup and sensitivity analyses that suggested that no major violations were present. The I 2 statistic for our network also suggested the presence of only moderate heterogeneity. Nonetheless, with differences in dose, use of cointerventions, and inherent differences between pharmacotherapies and behavioral therapies, this assumption may not have been fully satisfied. However, analyses stratified by type of intervention (pharmacotherapy versus behavioral therapy), type of CVD, and biochemical validation produced consistent results, suggesting that mild violations of this assumption are unlikely to have impacted our conclusions. We also assumed that the comparison groups of pharmacotherapies (placebo) and behavioral therapies (usual care) were equivalent; the sensitivity analysis testing this assumption produced similar results to those of our primary analysis. The second was the consistency assumption; our assessment of inconsistency plots suggested the presence of moderate heterogeneity in the network. Third, concerning the network geometry, although the network is not entirely symmetrical, the asymmetry of the network is likely because of greater safety concerns with the pharmacotherapies than with the behavioral therapies. The asymmetry may also be because of publication bias. The selection forces that shape the network, called comparator preference bias, are practically inevitable in network meta-analysis. 54 Fourth, we excluded conference abstracts because their results are often not final, and they contain insufficient information to assess study quality. Although we attempted to contact the authors of full-length articles to seek additional information, no attempt was made to contact the authors of conference abstracts. The exclusion of such abstracts may increase the risk of publication bias, potentially affecting the results of our network meta-analysis. Fifth, the exclusion of trials published in a language other than English or French may have also resulted in language bias. Sixth, most of our head-to-head evidence was obtained via indirect comparison because of the small number of RCTs directly comparing smoking cessation therapies to each other conducted in this patient population. Seventh, some studies were excluded because of the inclusion of patients not motivated to quit because differences in the distribution of an effect modifier such as motivation to quit may result in a violation of the consistency assumption. 15 Unfortunately, we were restricted to the aggregate data presented in the published articles. If patientlevel data had been available, we would have been able to use regression or stratification to account for differences in motivation to quit. Finally, we were unable to pool safety data from the pharmacotherapy trials because of inconsistent reporting of events and heterogeneous adverse event definitions.
Conclusions
Our network meta-analysis suggests that among patients who are motivated to quit smoking, varenicline and bupropion are efficacious for smoking cessation in patients with CVD, whereas available data about NRTs are inconclusive. Individual and telephone counseling also seem to be efficacious in this patient population. Overall, available evidence suggests that varenicline is the most efficacious smoking cessation therapy in patients with CVD who are motivated to quit smoking, although more safety data are needed. Given the small number of participants considered in these analyses, there remains a need for RCTs sufficiently powered to examine safety in this patient population as well as large, populationbased observational studies to examine this issue. 
